What You Should Know: - Hartwig Medical Foundation, a provider in using comprehensive genetic profiling to improve cancer treatment, and Ultima Genomics, a developer of groundbreaking next-generation sequencing (NGS) technology, announce a groundbreaking collaboration. -
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
News provided by
Share this article
Share this article
AUSTIN, Texas, May 28, 2021 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal s™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, (Docket No.6:21-cv-00540), alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act. Guardant s MRD test performance claims are incomplete or unsupported by clinical evidence, and can be misinterpreted by physicians and patients.
A recurrence occurs when cancer comes back after treatment. This can happen weeks, months, or even years after the primary or original cancer was treated. It is impossible to know for sure if the cancer will recur and timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery, can be challenging. Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for the identification of patients with minimal residual disease. Now researchers at Massachusetts General Hospital (MGH) report they have evaluated the first test that detects cancer DNA circulating in the blood of patients following treatment without knowing the particular mutations that were present in the patient’s tumor.